Sustained-release eye pharmaceutical Ocular Therapeutix files for a $86 million IPO
Ocular Therapeutix, which develops and markets eye therapeutics using its sustained-release hydrogel platform, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Bedford, MA-based company, which was founded in 2006 and began selling its first product in February, plans to list on the NASDAQ under the symbol OCUL. Ocular Therapeutix initially filed confidentially on April 29, 2014. Morgan Stanley, Cowen & Company and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.